Brief: Transgene Expects New Clinical Data On TG4001, TG6050 And BT-001 In H2

Transgene SA

14/05/2024 16:58

May 14 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE PROVIDES BUSINESS AND FINANCIAL UPDATE FOR Q1
2024
    * PHASE I DATA PRESENTED AT AACR 2024 DEMONSTRATING FIRST
SIGNS OF
CLINICAL BENEFIT IN ADJUVANT SETTING FOR HEAD AND NECK CANCER
PHASE II PART OF RANDOMIZED TRIAL TO START IN COMING WEEKS
    * FINANCIAL VISIBILITY UNTIL Q4 2025
    * NEW CLINICAL DATA EXPECTED ON TG4001, TG6050 AND BT-001 IN
H2
2024

Source text for Eikon:  ID:nGNE8J0qjr 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))